€1,025.5
Your prediction
Regeneron Pharmaceuticals Inc. Stock
Regeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Pros and Cons of Regeneron Pharmaceuticals Inc. in the next few years
Pros
Cons
Performance of Regeneron Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | -0.100% | -0.966% | -4.204% | 32.923% | 28.589% | 84.808% | 296.789% |
| Incyte Corp. | -2.440% | 2.408% | 4.079% | 5.350% | 3.419% | -9.444% | -17.573% |
| Exact Sciences | 0.640% | 7.077% | 17.005% | -11.499% | -9.033% | -32.401% | -34.770% |
| Amgen Inc. | 0.350% | 0.083% | 2.795% | 21.730% | 15.004% | 60.267% | 69.571% |
Comments
News
Biotech Breakout: Stocks for Your Watchlist
After a prolonged consolidation and downtrend following the pandemic-driven surge, the biotechnology sector is readying for a potential breakout and shifting its narrative. Represented by the
Prediction: These 2 Cathie Wood Stocks Could Crush the Market Through 2030
Is Cathie Wood a genius investor? The CEO of Ark Invest, an investment management firm, rose in prominence in the early days of the pandemic; her firm's actively managed ETFs performed well even as
Is Regeneron Pharmaceuticals Due for a Stock Split?
Regeneron Pharmaceuticals (NASDAQ: REGN) stock is trading above the $1,000 mark. It's at a high enough threshold that the company could decide to split its stock. That would lower the share price